MTOR and head and neck squamous cell carcinoma: Of note, only 56% of all PI3K/AKT/MTOR inhibitors are active, indicating the variability in the efficacy of these inhibitors, while 82% of the EGFR inhibitors tested in PRISM primary screen are active in HNSCC.